Could strontium ranelate have a synergistic role in the treatment of osteoporosis?

Journal of Bone and Mineral Research

Volumn 24, Issue 8, 2009, Pages 1354-1357

  Blake, Glen M ^a,c   Compston, Juliet E ^b   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; PLACEBO; STRONTIUM RANELATE;

BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; DRUG INHIBITION; DRUG WITHDRAWAL; FRACTURE; HUMAN; NONHUMAN; NOTE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; TREATMENT DURATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DRUG SYNERGISM; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; RATS; THIOPHENES;

EID: 68949100645     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090601     Document Type: Note

References (39)

1. Recker RR. Marin F. Ish-Shalom S, Moricke R, Hawkins F, Kapetanos G, de la Pena MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J 2009 Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24:1358-1368.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL. Marcus R, Ott SM, Torner JC, Quandt SA. Reiss TF, Ensrud KE 1996 Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541. (Pubitemid 26411651)
3. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082. (Pubitemid 29014065)
4. Harris ST. Watts NB, Genant HK, McKeever CD. Hangartner T, Keller M. Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352. (Pubitemid 29483192)
5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K. Cohen FJ, Eckert S, Ensrud KE, Avioli LV. Lips P. Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomised clinical trial. JAMA 282:637-645.
6. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y 2001 Effect of risedronate treatment on hip fracture risk in elderly women. N Engl J Med 344:333-340. (Pubitemid 32107641)
7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK. Wang O, Milak BH 2001 Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344:1434-1441.
8. Chesnut CH, Skag A, Christiansen C, Recker R. Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249. (Pubitemid 41094364)
9. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel E-M, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster J-Y 2004 The effects of Strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468. (Pubitemid 38133766)
10. Reginster J-Y, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Diaz Curiel M, Sawicki A, Goemarere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 90:2816-2822.
11. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822. (Pubitemid 46698462)
12. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768. (Pubitemid 41138965)
13. Boivin G, Meunier PJ 2002 Effects of bisphosphonates on matrix mineralisation. J Musculoskelet Neuronal Interact 2:538-543.
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 112:281-289. (Pubitemid 34219441)
15. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
16. Compston JE 2007 Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure. Bone 40:1447-1452. (Pubitemid 46756408)
17. Marie PJ, Hott M. Modrowski D. De Pollak C, Guillemain J, Deloffre P, Tsouderos Y 1993 An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607-615. (Pubitemid 23127921)
18. Canalis E. Hott M, Deloffre P, Tsouderos Y, Marie PJ 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517-523. (Pubitemid 26257871)
19. Marie PJ, Ammann P, Boivin G, Rey C 2001 Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121-129. (Pubitemid 32912229)
20. Marie PJ 2005 Strontium ranelate: A novel mode of action optimizing bone formation and bone resorption. Osteoporos Int 16(Suppl 1):S7-S10. (Pubitemid 40768190)
21. Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB 2008 Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19:1331-1341.
22. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C 2002 Prevention of early postmenopausal bone loss by strontium ranelate: The randomised, two-year, double-masked, dose-ranging, placebo-controlled PREVOS study. Osteoporos Int 13:925-931. (Pubitemid 36050269)
23. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Neilsen S, de Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomised placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066.
24. Brixen K, Krogsggaard K, Chritsgau S, Weis M, Eastell R 2008 Effect of three doses of strontium malonate (NB SlOl) on markers of bone turnover: The STRONG study. Calcif Tissue Int 82(Suppl 1):S217.
25. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ 2008 Histomorpometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215-222. (Pubitemid 351160035)
26. Farley D, Boivin G, Panczer G, Lalande A, Meunier PJ 2005 Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 20:1569-1578. (Pubitemid 41243546)
27. Pors Nielsen S, Slosman D, Sorensen OH, Basse-Cathelinat B, De Casin P, Roux C, Meunier PJ 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual x-ray absorptiometry. J Clin Densitom 2:371-379.
28. Blake GM, Fogelman I 2006 Theoretical model for the interpretation of BMD scans in patients stopping strontium rane-late treatment. J Bone Miner Res 21:1417-1424. (Pubitemid 44300048)
29. Boivin G, Farley D, Simi C, Meunier PJ 2006 Bone strontium distribution and degree of mineralization of bone in postmenopausal osteoporotic women treated with strontium ranelate for 2 and 3 years. Osteoporos Int 17(Suppl 2):S210.
30. Blake GM, Fogelman I 2007 The correction of BMD measurements for bone strontium content. J Clin Densitom 10:259-265. (Pubitemid 47198528)
31. Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R 2007 Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22:1419-1425. (Pubitemid 351339686)
32. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076-3081. (Pubitemid 47236373)
33. Ortolani S, Diaz-Curiel M 2006 Strontium ranelate: Changes in BMD one year after treatment discontinuation. J Bone Miner Res 21:S1;S189.
34. Blake GM, Lewiecki EM, Kendler DL, Fogelman I 2007 A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 10:113-119. (Pubitemid 46678864)
35. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215. (Pubitemid 37152030)
36. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751. (Pubitemid 41094385)
37. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860.
38. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565. (Pubitemid 41138937)
39. Boivin GY, Chavassieux PM, Santora A, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694. (Pubitemid 30808808)